Efficacy of Relebactam (MK-7655) in Combination with Imipenem-Cilastatin in Murine Infection Models

DOI: 10.1128/aac.02577-17
Antimicrobial Agents and Chemotherapy, 2018, 62, .

#	Paper	IF	Citations
23	Pharmacokinetics-pharmacodynamics of β-lactamase inhibitors: are we missing the target?. *Expert Review of Anti-Infective Therapy*, **2019**, 17, 571-582	5.5	12
22	The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections. *Expert Opinion on Pharmacotherapy*, **2019**, 20, 2169-2184	4	57
21	Evaluating the Efficacies of Carbapenem/β-Lactamase Inhibitors Against Carbapenem-Resistant Gram-Negative Bacteria and. *Frontiers in Microbiology*, **2019**, 10, 933	5.7	10
20	Antibacterial effect of imipenem/relebactam on aerobic Gram-negative bacilli: in vitro simulations of 7 or 14 day human exposures. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 1945-1951	5.1	3
19	A First-in-Human Safety, Tolerability, and Pharmacokinetics Study of Benapenem in Healthy Chinese Volunteers. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	5
18	β-Lactamase Inhibitors To Restore the Efficacy of Antibiotics against Superbugs. *Journal of Medicinal Chemistry*, **2020**, 63, 1859-1881	8.3	53
17	In Vitro and In Vivo Evaluations of β-Lactam/β-Lactamase Mono- and Combined Therapies against Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan. *Microorganisms*, **2020**, 8,	4.9	2
16	In vivo activity of human-simulated regimens of imipenem alone and in combination with relebactam against Pseudomonas aeruginosa in the murine thigh infection model. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 2197-2205	5.1	5
15	Potent Antibiotics Active against Multidrug-Resistant Gram-Negative Bacteria. *Chemical and Pharmaceutical Bulletin*, **2020**, 68, 182-190	1.9	7
14	Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology. *Current Infectious Disease Reports*, **2020**, 22, 6	3.9	23
13	Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections. *Pharmacotherapy*, **2020**, 40, 343-356	5.8	30
12	Clinical Pharmacokinetics and Pharmacodynamics of Imipenem-Cilastatin/Relebactam Combination Therapy. *Clinical Pharmacokinetics*, **2020**, 59, 567-573	6.2	8
11	The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study. *Journal of Infection and Chemotherapy*, **2021**, 27, 262-270	2.2	7
10	Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections. *Drugs*, **2021**, 81, 377-388	9.1	9
9	Bicyclic Boronate β-Lactamase Inhibitors: The Present Hope against Deadly Bacterial Pathogens. *Advanced Therapeutics*, **2021**, 4, 2000246	4.9	8
8	Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan. *Journal of Microbiology, Immunology and Infection*, **2021**, 55, 86-86	8.5	6
7	Evaluation of the Organotellurium Compound AS101 for Treating Colistin- and Carbapenem-Resistant. *Pharmaceuticals*, **2021**, 14,	5.2	4

6	Discovery and Chemical Development of Relebactam: A Potent β-Lactamase Inhibitor in Combination with Primaxin® for the Treatment of Serious and Antibiotic-Resistant Bacterial Infections. *ACS Symposium Series*, **2020**, 253-284	0.4	
5	Impact of a Novel Anticoccidial Analogue on Systemic Infection in a Bioluminescent Mouse Model.. *Antibiotics*, **2022**, 11,	4.9	0
4	Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments.. *Journal of Antimicrobial Chemotherapy*, **2022**,	5.1	5
3	Image_1.TIF. **2019**,		
2	Image_2.TIF. **2019**,		
1	New Perspectives on Antimicrobial Agents: Imipenem-Relebactam. *Antimicrobial Agents and Chemotherapy*,	5.9	0